169 related articles for article (PubMed ID: 8099547)
1. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures.
Jensen PH; Lorand L; Ebbesen P; Gliemann J
Eur J Biochem; 1993 May; 214(1):141-6. PubMed ID: 8099547
[TBL] [Abstract][Full Text] [Related]
2. A unique interhelical insertion in plasminogen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cross-linking.
Jensen PH; Schüler E; Woodrow G; Richardson M; Goss N; Højrup P; Petersen TE; Rasmussen LK
J Biol Chem; 1994 May; 269(21):15394-8. PubMed ID: 7910824
[TBL] [Abstract][Full Text] [Related]
3. Characterization of thrombospondin as a substrate for factor XIII transglutaminase.
Lynch GW; Slayter HS; Miller BE; McDonagh J
J Biol Chem; 1987 Feb; 262(4):1772-8. PubMed ID: 2879842
[TBL] [Abstract][Full Text] [Related]
4. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2).
Ritchie H; Lawrie LC; Mosesson MW; Booth NA
Ann N Y Acad Sci; 2001; 936():215-8. PubMed ID: 11460477
[TBL] [Abstract][Full Text] [Related]
5. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators.
Barsigian C; Stern AM; Martinez J
J Biol Chem; 1991 Nov; 266(33):22501-9. PubMed ID: 1682320
[TBL] [Abstract][Full Text] [Related]
6. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein (a) is a substrate for factor XIIIa and tissue transglutaminase.
Borth W; Chang V; Bishop P; Harpel PC
J Biol Chem; 1991 Sep; 266(27):18149-53. PubMed ID: 1680857
[TBL] [Abstract][Full Text] [Related]
8. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking.
Achyuthan KE; Dobson JV; Greenberg CS
Biochim Biophys Acta; 1986 Aug; 872(3):261-8. PubMed ID: 2873839
[TBL] [Abstract][Full Text] [Related]
9. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin.
Ritchie H; Robbie LA; Kinghorn S; Exley R; Booth NA
Thromb Haemost; 1999 Jan; 81(1):96-103. PubMed ID: 10348718
[TBL] [Abstract][Full Text] [Related]
10. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
[TBL] [Abstract][Full Text] [Related]
11. Vitronectin is a substrate for transglutaminases.
Sane DC; Moser TL; Pippen AM; Parker CJ; Achyuthan KE; Greenberg CS
Biochem Biophys Res Commun; 1988 Nov; 157(1):115-20. PubMed ID: 2461707
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-2 is expressed in different types of congenital ichthyosis: in vivo evidence for its cross-linking into the cornified cell envelope by transglutaminase-1.
Oji V; Oji ME; Adamini N; Walker T; Aufenvenne K; Raghunath M; Traupe H
Br J Dermatol; 2006 May; 154(5):860-7. PubMed ID: 16634887
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.
Mikus P; Urano T; Liljeström P; Ny T
Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
16. C1 inhibitor cross-linking by tissue transglutaminase.
Hauert J; Patston PA; Schapira M
J Biol Chem; 2000 May; 275(19):14558-62. PubMed ID: 10799541
[TBL] [Abstract][Full Text] [Related]
17. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.
Dickinson JL; Norris BJ; Jensen PH; Antalis TM
Cell Death Differ; 1998 Feb; 5(2):163-71. PubMed ID: 10200461
[TBL] [Abstract][Full Text] [Related]
18. Urokinase binds to a plasminogen activator inhibitor type-2-like molecule in placental microvillous membranes.
Jensen PH; Nykjaer A; Andreasen PA; Lund LR; Astedt B; Lecander I; Gliemann J
Biochim Biophys Acta; 1989 Nov; 986(1):135-40. PubMed ID: 2819091
[TBL] [Abstract][Full Text] [Related]
19. The comparative ability of plasma and tissue transglutaminases to use collagen as a substrate.
Jeleńska MM; Fesüs L; Kopeć M
Biochim Biophys Acta; 1980 Dec; 616(2):167-78. PubMed ID: 6111338
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
